Recent Press Releases

FDA approves Zydelig for three types of blood cancers

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. Zydelig is being granted traditional approval to treat patients whose...

U.S. Food and Drug Administration Approves Gilead's Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma

-- 82 Percent Reduction in Risk of Disease Progression or Death When Combined with Rituximab Compared to Rituximab Alone in Patients with Relapsed Chronic Lymphocytic Leukemia -- FOSTER CITY,...

Seven pharma companies offer up compounds to UK researchers

UK researchers will be granted access to a 'virtual library' of deprioritised pharmaceutical compounds through a new partnership between the Medical Research Council (MRC) and seven global...

Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer

SAN DIEGO -- Halozyme Therapeutics, Inc. today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic...

Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial

Treatment with VGX-3100 induces regression of precancerous cervical disease and clears HPV infection with robust T cell responses PLYMOUTH MEETING, Pa., July 23, 2014 /PRNewswire/ -- Inovio...

Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures

• Brivaracetam is the newest investigational medicine to emerge from UCB's rich late-stage pipeline • Submissions to US and EU regulatory authorities planned for early 2015: subject to...

FDA Approves Eagle Pharmaceuticals' Ryanodex® for the Treatment of Malignant Hyperthermia

FDA Approves Eagle Pharmaceuticals' Ryanodex® for the Treatment of Malignant Hyperthermia -- Novel Antidote Enables Quicker Response to Inherited Life-Threatening Condition ---- Orphan Drug...

Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen

Strengthens Leadership Position in Treatments for Hunter syndrome and Commitment to MPS II Patient Community LEXINGTON, Massachusetts, July 23, 2014 -- Shire plc (LSE: SHP, NASDAQ: SHPG), the global...

Sofinnova Raises $500 Million Biotech Venture Fund

Sofinnova Raises $500 Million Biotech Venture Fund SVP IX fund to invest primarily in late-stage biopharmaceutical companies MENLO PARK, Calif., July 23, 2014 /PRNewswire/ -- Sofinnova Ventures, a...

Puma Biotechnology Announces Amendment to Neratinib Licensing Agreement with Pfizer

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (PBYI), a development stage biopharmaceutical company, announced an amendment to its licensing agreement with Pfizer for Puma's...

Puma Biotechnology Announces Positive Top Line Results from Phase III PB272 Trial in Adjuvant Breast Cancer (ExteNET Trial)

Neratinib Achieves Statistically Significant Improvement in Disease Free Survival Company Plans to File for Regulatory Approval in First Half of 2015 LOS ANGELES--(BUSINESS WIRE)-- Puma...

Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept

Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept MONMOUTH JUNCTION, N.J., July 22, 2014 /PRNewswire/ -- Vernalis plc UK:VER +1.56% and Tris Pharma, Inc....

Phosphagenics Completes First Tranche of A$19.3 Million Capital Raising

Phosphagenics Completes First Tranche of A$19.3 Million Capital Raising - Sold 153 million shares at A$0.08 per share- A$3 million Share Purchase Plan expected to close July 29 MELBOURNE, Australia,...

ZIOPHARM Announces Expansion of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon and Clinical Program Update

ZIOPHARM Announces Expansion of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon and Clinical Program Update BOSTON and GERMANTOWN, Md., Jul 22, 2014 (GLOBE NEWSWIRE via COMTEX) -- ...

SAGE Therapeutics Receives Fast Track Designation for Lead Compound SAGE-547 to Treat Status Epilepticus

CAMBRIDGE, Mass.--SAGE Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, announced today that...

Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020

PORTLAND, Oregon, July 21, 2014 /PRNewswire via COMTEX/ -- PORTLAND, Oregon, July 21, 2014 /PRNewswire/ -- A new report by Allied Market Research titled, "Global biosimilars/follow-on-biologics...

MedImmune and Advaxis partner on immuno-oncology combination clinical trial

Tuesday, 22 July 2014 AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based...

International team sheds new light on biology underlying schizophrenia

Cambridge, Mass. Mon. July 21, 2014 – As part of a multinational, collaborative effort, researchers from the Broad Institute, Massachusetts General Hospital (MGH), and scores of other...

$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research

Transformative partnership with Ted Stanley will spur researchers to reveal biology of psychiatric disorders -- A personal mission becomes an international pursuit to help others -- Cambridge, MA....

Axiogenesis Joins Industry Consortium Focused on Advancing Predictive Technologies for Cardiac Safety Testing

Washington, DC USA and Cologne GERMANY Axiogenesis AG, a leading global provider of in vitro models of healthy and diseased human cell types derived from induced pluripotent stem cells (iPSC),...